LogicBio Therapeutics, Inc. (LOGC:NASDAQ) Investor Relations Material

Overview

LogicBio Therapeutics is a biotech company focused on expanding the applications of genetic medicine through targeted delivery platforms. Their proprietary genome editing technology platform, GeneRide, uses homologous recombination to enable the site-specific integration of therapeutic transgenes without the need for nucleases or external promoters. The company is also working on developing a Next Generation Capsid platform for gene editing and gene therapies, which could be used for both internal development and potential collaborations. LogicBio is based in Lexington, Mass.

Frequently Asked Questions

What is LogicBio Therapeutics, Inc.'s ticker?

LogicBio Therapeutics, Inc.'s ticker is LOGC

What exchange is LogicBio Therapeutics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are LogicBio Therapeutics, Inc.'s headquarters?

They are based in Lexington, Massachusetts

How many employees does LogicBio Therapeutics, Inc. have?

There are 11-50 employees working at LogicBio Therapeutics, Inc.

What is LogicBio Therapeutics, Inc.'s website?

It is https://www.logicbio.com/

What type of sector is LogicBio Therapeutics, Inc.?

LogicBio Therapeutics, Inc. is in the Healthcare sector

What type of industry is LogicBio Therapeutics, Inc.?

LogicBio Therapeutics, Inc. is in the Biotechnology industry

Who are LogicBio Therapeutics, Inc.'s peers and competitors?

The following five companies are LogicBio Therapeutics, Inc.'s industry peers:

- Coherus BioSciences

- Siren Gold Limited

- OKYO Pharma Limited

- Akari Therapeutics Plc

- Agenus